Cargando…
Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis
The success of allogeneic hematopoietic stem cell transplant for hematological malignancies is heavily dependent on the availability of suitable donors. Haploidentical donor (HID) and matched sibling donor (MSD) are two important donor options providing faster and easier sources of stem cells, howev...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193779/ https://www.ncbi.nlm.nih.gov/pubmed/37198603 http://dx.doi.org/10.1186/s12967-023-04168-6 |
_version_ | 1785043886398242816 |
---|---|
author | Wu, Hengwei Zhao, Yeqian Gao, Fei Shi, Jimin Luo, Yi Yu, Jian Lai, Xiaoyu Liu, Lizhen Fu, Huarui Qian, Pengxu Huang, He Zhao, Yanmin |
author_facet | Wu, Hengwei Zhao, Yeqian Gao, Fei Shi, Jimin Luo, Yi Yu, Jian Lai, Xiaoyu Liu, Lizhen Fu, Huarui Qian, Pengxu Huang, He Zhao, Yanmin |
author_sort | Wu, Hengwei |
collection | PubMed |
description | The success of allogeneic hematopoietic stem cell transplant for hematological malignancies is heavily dependent on the availability of suitable donors. Haploidentical donor (HID) and matched sibling donor (MSD) are two important donor options providing faster and easier sources of stem cells, however, due to confounding factors present in most retrospective studies, the validity of comparing outcomes between these two donor types remains uncertain. We conducted a post-hoc analysis of a prospective clinical trial (trial registration: Chinese Clinical Trial Registry; #ChiCTR-OCH-12002490; registered 22 February 2012; https://www.chictr.org.cn/showproj.aspx?proj=7061) to compare outcomes of HID versus MSD peripheral blood stem cell-derived transplants in patients with hematologic malignancies between 2015 and 2022. All HID-receiving patients had antithymocyte globulin-based conditioning. Propensity score matching was employed to minimize potential confounding factors between the two cohorts. A total of 1060 patients were initially reviewed and then 663 patients were ultimately included in the analysis after propensity score matching. The overall survival, relapse-free survival, non-relapse mortality rate and cumulative incidence of relapse were similar between HID and MSD cohorts. Subgroup analysis revealed that patients with positive measurable residual disease in first complete remission may have better overall survival with an HID transplant. The present demonstrated that haploidentical transplants can provide outcomes comparable to conventional MSD transplants, and HID should be recommended as one of the optimal donor choices for patients with positive measurable residual disease in first complete remission. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04168-6. |
format | Online Article Text |
id | pubmed-10193779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101937792023-05-19 Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis Wu, Hengwei Zhao, Yeqian Gao, Fei Shi, Jimin Luo, Yi Yu, Jian Lai, Xiaoyu Liu, Lizhen Fu, Huarui Qian, Pengxu Huang, He Zhao, Yanmin J Transl Med Research The success of allogeneic hematopoietic stem cell transplant for hematological malignancies is heavily dependent on the availability of suitable donors. Haploidentical donor (HID) and matched sibling donor (MSD) are two important donor options providing faster and easier sources of stem cells, however, due to confounding factors present in most retrospective studies, the validity of comparing outcomes between these two donor types remains uncertain. We conducted a post-hoc analysis of a prospective clinical trial (trial registration: Chinese Clinical Trial Registry; #ChiCTR-OCH-12002490; registered 22 February 2012; https://www.chictr.org.cn/showproj.aspx?proj=7061) to compare outcomes of HID versus MSD peripheral blood stem cell-derived transplants in patients with hematologic malignancies between 2015 and 2022. All HID-receiving patients had antithymocyte globulin-based conditioning. Propensity score matching was employed to minimize potential confounding factors between the two cohorts. A total of 1060 patients were initially reviewed and then 663 patients were ultimately included in the analysis after propensity score matching. The overall survival, relapse-free survival, non-relapse mortality rate and cumulative incidence of relapse were similar between HID and MSD cohorts. Subgroup analysis revealed that patients with positive measurable residual disease in first complete remission may have better overall survival with an HID transplant. The present demonstrated that haploidentical transplants can provide outcomes comparable to conventional MSD transplants, and HID should be recommended as one of the optimal donor choices for patients with positive measurable residual disease in first complete remission. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04168-6. BioMed Central 2023-05-18 /pmc/articles/PMC10193779/ /pubmed/37198603 http://dx.doi.org/10.1186/s12967-023-04168-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wu, Hengwei Zhao, Yeqian Gao, Fei Shi, Jimin Luo, Yi Yu, Jian Lai, Xiaoyu Liu, Lizhen Fu, Huarui Qian, Pengxu Huang, He Zhao, Yanmin Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis |
title | Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis |
title_full | Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis |
title_fullStr | Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis |
title_full_unstemmed | Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis |
title_short | Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis |
title_sort | haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193779/ https://www.ncbi.nlm.nih.gov/pubmed/37198603 http://dx.doi.org/10.1186/s12967-023-04168-6 |
work_keys_str_mv | AT wuhengwei haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT zhaoyeqian haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT gaofei haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT shijimin haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT luoyi haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT yujian haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT laixiaoyu haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT liulizhen haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT fuhuarui haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT qianpengxu haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT huanghe haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis AT zhaoyanmin haploidenticaltransplantsdeliverequaloutcomestomatchedsiblingtransplantsapropensityscorematchedanalysis |